April 2022
BCCHPSM Drug List Change Notification
Blue Cross and Blue Shield of Illinois (BCBSIL) would like to inform you of the following drug list changes effective April 1, 2022. The table below shows product status changes on the formulary for Blue Cross Community Health PlansSM (BCCHP). To improve patient experience related to this change, please consider transitioning your BCCHP patients to the preferred product or submit prior authorization before the effective date. Participating pharmacies may reach out to you to provide a new prescription for your covered patients.
Preferred Products Starting April 1, 2022: |
Non-Preferred Products Starting April 1, 2022: |
ADVAIR DISKU AER 100/50 |
FLUTIC/SALME AER 100/50 |
ADVAIR DISKU AER 250/50 |
WIXELA INHUB AER 100/50 |
ADVAIR DISKU AER 500/50 |
WIXELA INHUB AER 250/50 |
ADVAIR HFA AER 45/21 |
FLUTIC/SALME AER 250/50 |
ADVAIR HFA AER 115/21 |
WIXELA INHUB AER 500/50 |
ADVAIR HFA AER 230/21 |
BEVESPI AER 9-4.8MCG |
AIRDUO DGHLR INH 113-14 |
|
AIRDUO RESPI INH 55-14 |
|
AIRDUO DGHLR INH 232-14 |
|
AIRDUO RESPI INH 113-14 |
|
AIRDUO RESPI INH 232-14 |
|
AIRDUO DGHLR INH 55-14 |
|
ANORO ELLIPT AER 62.5-25 |
|
INCRUSE ELPT INH 62.5MCG |
|
SPIRIVA SPR 2.5MCG |
|
Members can call the Member Services phone number on their BCBSIL ID card if they have any questions.
If you have any questions regarding processing claims, please call the Prime Therapeutics Contact Center at 800-821-4795.
The above material is for informational purposes only and is not intended to be a substitute for the independent medical judgment of a physician. Physicians and other health care providers are encouraged to use their own best medical judgment based upon all available information and the condition of the patient in determining the best course of treatment.
Trademarks are the property of their respective owners.
Prime Therapeutics LLC (Prime) is a separate pharmacy benefit management company contracted by BCBSIL to provide pharmacy benefit management and other related services. BCBSIL, as well as several Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.